Related Experiment Video
Updated: Apr 11, 2026
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Chronic heart failure: what does the horizon look like?
1Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
Insights
Novel therapies like LCZ696 and ivabradine show promise for heart failure with reduced ejection fraction (HFrEF). However, effective treatments for heart failure with preserved ejection fraction (HFpEF) remain elusive, despite ongoing research.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Heart failure, encompassing both reduced (HFrEF) and preserved ejection fraction (HFpEF) types, presents a significant global health challenge.
- Recent advancements aim to improve outcomes and reduce hospitalizations for heart failure patients.
Purpose of the Study:
- To review the latest developments in HFrEF and HFpEF treatment strategies.
- To highlight novel therapeutic agents and monitoring devices impacting heart failure care.
Main Methods:
- Review of recent clinical trials and FDA-approved therapies for HFrEF and HFpEF.
- Analysis of efficacy and safety data for new heart failure interventions.
Main Results:
- LCZ696 (valsartan and neprilysin inhibitor) significantly reduced mortality and hospitalizations in HFrEF compared to enalapril.
- Ivabradine and coenzyme Q10 demonstrated efficacy as adjunctive therapies in HFrEF.
- Clinical trials for HFpEF have yielded disappointing results thus far.
- A novel pulmonary artery pressure monitoring device received FDA approval, potentially reducing readmissions.
Conclusions:
- Novel therapies such as LCZ696 and ivabradine offer new hope for managing HFrEF.
- Current evidence does not support novel interventions modifying the natural course of HFpEF.
- Pulmonary artery pressure monitoring may offer a future strategy for reducing HFpEF readmissions.
Purpose Of Review:
This review highlights the most recent developments in the field of heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF).
Recent Findings:
The largest trial to date in patients with HFrEF demonstrated that LCZ696, a novel combination drug of valsartan and a neprilysin inhibitor, as compared with enalapril, significantly reduced the death rates from any cause and from cardiovascular causes and the rates of hospitalizations for worsening heart failure. Both ivabradine, a novel heart rate lowering therapy, currently approved by the Food and Drug Administration (FDA), and coenzyme Q10, a powerful antioxidant, when used as adjunctive treatment in HFrEF have also been shown to be efficacious in reducing important heart failure-related cardiovascular adverse events. In contrast, clinical trials in HFpEF remain disappointing; however, the recent FDA approval of a novel pulmonary artery pressure monitoring device has the potential to reduce heart failure readmissions in patients with HFpEF or HFrEF.
Summary:
Novel therapies including LCZ696 and ivabradine have the potential to help curb the burden of heart failure in patients with HFrEF. For now, there continues to remains no clear evidence that novel therapeutic interventions modify the natural history of HFpEF.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:27Heart Failure I: Introduction
01:29Heart Failure II: Pathophysiology
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies